Cargando…
P1140: TIME TO TUMOR, SYMPTOMATIC AND LABORATORY RESPONSES FOLLOWING SILTUXIMAB TREATMENT IN IDIOPATHIC MULTICENTRIC CASTLEMAN DISEASE
| Autores principales: | , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9429592/ http://dx.doi.org/10.1097/01.HS9.0000847428.60021.87 |
| _version_ | 1784779504072261632 |
|---|---|
| author | van Rhee, F. Rosenthal, A. Kanhai, K. Martin, R. Nishimura, K. Hoering, A. Fajgenbaum, D. |
| author_facet | van Rhee, F. Rosenthal, A. Kanhai, K. Martin, R. Nishimura, K. Hoering, A. Fajgenbaum, D. |
| author_sort | van Rhee, F. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9429592 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-94295922022-08-31 P1140: TIME TO TUMOR, SYMPTOMATIC AND LABORATORY RESPONSES FOLLOWING SILTUXIMAB TREATMENT IN IDIOPATHIC MULTICENTRIC CASTLEMAN DISEASE van Rhee, F. Rosenthal, A. Kanhai, K. Martin, R. Nishimura, K. Hoering, A. Fajgenbaum, D. Hemasphere Posters Lippincott Williams & Wilkins 2022-06-23 /pmc/articles/PMC9429592/ http://dx.doi.org/10.1097/01.HS9.0000847428.60021.87 Text en Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially. |
| spellingShingle | Posters van Rhee, F. Rosenthal, A. Kanhai, K. Martin, R. Nishimura, K. Hoering, A. Fajgenbaum, D. P1140: TIME TO TUMOR, SYMPTOMATIC AND LABORATORY RESPONSES FOLLOWING SILTUXIMAB TREATMENT IN IDIOPATHIC MULTICENTRIC CASTLEMAN DISEASE |
| title | P1140: TIME TO TUMOR, SYMPTOMATIC AND LABORATORY RESPONSES FOLLOWING SILTUXIMAB TREATMENT IN IDIOPATHIC MULTICENTRIC CASTLEMAN DISEASE |
| title_full | P1140: TIME TO TUMOR, SYMPTOMATIC AND LABORATORY RESPONSES FOLLOWING SILTUXIMAB TREATMENT IN IDIOPATHIC MULTICENTRIC CASTLEMAN DISEASE |
| title_fullStr | P1140: TIME TO TUMOR, SYMPTOMATIC AND LABORATORY RESPONSES FOLLOWING SILTUXIMAB TREATMENT IN IDIOPATHIC MULTICENTRIC CASTLEMAN DISEASE |
| title_full_unstemmed | P1140: TIME TO TUMOR, SYMPTOMATIC AND LABORATORY RESPONSES FOLLOWING SILTUXIMAB TREATMENT IN IDIOPATHIC MULTICENTRIC CASTLEMAN DISEASE |
| title_short | P1140: TIME TO TUMOR, SYMPTOMATIC AND LABORATORY RESPONSES FOLLOWING SILTUXIMAB TREATMENT IN IDIOPATHIC MULTICENTRIC CASTLEMAN DISEASE |
| title_sort | p1140: time to tumor, symptomatic and laboratory responses following siltuximab treatment in idiopathic multicentric castleman disease |
| topic | Posters |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9429592/ http://dx.doi.org/10.1097/01.HS9.0000847428.60021.87 |
| work_keys_str_mv | AT vanrheef p1140timetotumorsymptomaticandlaboratoryresponsesfollowingsiltuximabtreatmentinidiopathicmulticentriccastlemandisease AT rosenthala p1140timetotumorsymptomaticandlaboratoryresponsesfollowingsiltuximabtreatmentinidiopathicmulticentriccastlemandisease AT kanhaik p1140timetotumorsymptomaticandlaboratoryresponsesfollowingsiltuximabtreatmentinidiopathicmulticentriccastlemandisease AT martinr p1140timetotumorsymptomaticandlaboratoryresponsesfollowingsiltuximabtreatmentinidiopathicmulticentriccastlemandisease AT nishimurak p1140timetotumorsymptomaticandlaboratoryresponsesfollowingsiltuximabtreatmentinidiopathicmulticentriccastlemandisease AT hoeringa p1140timetotumorsymptomaticandlaboratoryresponsesfollowingsiltuximabtreatmentinidiopathicmulticentriccastlemandisease AT fajgenbaumd p1140timetotumorsymptomaticandlaboratoryresponsesfollowingsiltuximabtreatmentinidiopathicmulticentriccastlemandisease |